BYSI BeyondSpring, Inc.
Mergers ·
BeyondSpring closed the sale of the holding company for its China unit, Bulin, on September 30, 2026. The buyer paid no cash at closing. It took on the China portion of the DUBLIN-4 Phase 3 trial in exchange, and BeyondSpring will receive the clinical data from that work.
BeyondSpring Inc. completed the sale of BeyondSpring Ltd. to Biolin Investment Limited on September 30, 2026. No cash changed hands. The company received a license to China trial data, a funding commitment from the buyer, and a clawback, and it gave up control of SEED Therapeutics.
BeyondSpring Inc. received a Nasdaq letter on September 29, 2026 saying its market value of listed securities has been below $35 million for 30 consecutive business days. It has until March 29, 2027 to regain compliance, and its shares keep trading in the meantime.
BeyondSpring has set up an at-the-market program through Citizens for up to 9,200,000 ordinary shares, capped at $11,942,800 by its public float limit. The prospectus supplement is dated September 29, 2026, and the same day the company agreed to sell its Chinese subsidiary to Biolin Investment Limited.
Nasdaq told BeyondSpring on September 17, 2026 that its ordinary shares closed below $1.00 for 30 consecutive business days. Trading continues during a 180 calendar day compliance period that ends March 16, 2027.
BeyondSpring is a clinical stage global biopharmaceutical company focused on developing innovative therapies for patients with high unmet medical needs. Its first-in-class lead asset, plinabulin, is a brain-penetrant microtubule modulator that the company says may help mitigate acquired resistance after immune checkpoint inhibitor treatment. Plinabulin has been administered to over 700 cancer patients and is being developed as a pipeline in a drug, including for reducing chemotherapy-induced neutropenia. After a successful Phase 3 study, DUBLIN-3, in non-small cell lung cancer, a confirmatory global Phase 3 study is ongoing in second- and third-line NSCLC with EGFR wild type after progression on prior immune checkpoint inhibitors. The company is also developing three small molecule immune agents at preclinical stages. It founded SEED Therapeutics Inc. and continues to own an equity stake in it. SEED uses targeted protein degradation technology, has advanced a novel RBM39 degrader into Phase 1 clinical studies in January 2026, and partners with Eli Lilly and Co. and Eisai Co., Ltd.
| Product or program | What it is | Stage |
|---|---|---|
| Plinabulin | Brain-penetrant microtubule modulator being developed for NSCLC after checkpoint inhibitor treatment | confirmatory global Phase 3 study in second- and third-line NSCLC with EGFR wild type |
| RBM39 degrader (SEED Therapeutics) | Oncology degrader from the SEED targeted protein degradation platform | Phase 1 clinical studies started January 2026 |
| Three small molecule immune agents | Immune agents in the company pipeline | preclinical |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $4.4 million | $2.6 million |
| Net income (loss) | -$1.0 million | -$11.1 million |
| Cash from operations | -$19.8 million | -$16.4 million |
| Cash and equivalents | $7.8 million | $2.9 million |
| Short-term investments | $4.8 million | $0 |
Our latest story on this, dated Sep 29, 2026: "BeyondSpring sets up at-the-market program for up to $11,942,800 in shares". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 2, 2026: "BeyondSpring gets Nasdaq notice after market value falls below $35 million". The story links the filing or release it is based on. Read the story.
BeyondSpring, Inc. trades under the ticker BYSI on NASDAQ.
BeyondSpring, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for BeyondSpring, Inc. is 1677940. Its filings are on SEC EDGAR.
41,119,820 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-14.
Our directory records BeyondSpring, Inc. under United States.
Our directory classifies BeyondSpring, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for BeyondSpring, Inc. is KYG108301006.
aibio.space lists BeyondSpring, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
BeyondSpring is a clinical stage global biopharmaceutical company focused on developing innovative therapies for patients with high unmet medical needs. Its first-in-class lead asset, plinabulin, is a brain-penetrant microtubule modulator that the company says may help mitigate acquired resistance after immune checkpoint inhibitor treatment.
Plinabulin: Brain-penetrant microtubule modulator being developed for NSCLC after checkpoint inhibitor treatment Stage: confirmatory global Phase 3 study in second- and third-line NSCLC with EGFR wild type.
RBM39 degrader (SEED Therapeutics): Oncology degrader from the SEED targeted protein degradation platform Stage: Phase 1 clinical studies started January 2026.
BeyondSpring, Inc. reported a net loss of $1.0 million for the fiscal year ended Dec 31, 2025, and used $19.8 million of cash in operations, per its annual report to the SEC.
$4.4 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio